Dr. Michael E. Tarnoff M.D. serves as Independent Director of the Company. Since June 2019, Dr. Tarnoff has been Chair of the Department of Surgery and Surgeon-in-Chief at Tufts Medical Center and Tufts University School of Medicine in Boston, Massachusetts. Dr. Tarnoff has been a surgeon at Tufts since 2001. Dr. Tarnoff was Chief Medical Officer at Medtronic from January 2015 through August 2019. From 2008 until its acquisition by Medtronic in 2015, Dr. Tarnoff served as the Chief Medical Officer and Senior Vice President for Medical Affairs at Covidien plc. Dr. Tarnoff received a BA in psychology from Washington University in St Louis, and received an MD from and completed his residency in General Surgery at the University and Medicine and Dentistry of New Jersey. Dr. Tarnoff also completed a fellowship in Advanced Minimally Invasive Surgery at the Cleveland Clinic in Cleveland, Ohio. Dr. Tarnoff is a member of our Nominating, Compliance and Corporate Governance Committee.
As the Independent Director of Angiodynamic Inc, the total compensation of Michael Tarnoff at Angiodynamic Inc is $37,726. There are 17 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.
Michael Tarnoff is 51, he's been the Independent Director of Angiodynamic Inc since 2019. There are 19 older and 6 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.
Michael's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 21 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman oraz Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: